A total of 56 obese (body mass index, 43±7 kg/m 2 ) and 14 nonobese (body mass index, 25.7±2 kg/m 2 ) subjects Objective-Increased visceral adiposity has been closely linked to insulin resistance, endothelial dysfunction, and cardiometabolic disease in obesity, but pathophysiological mechanisms are poorly understood. We sought to investigate mechanisms of vascular insulin resistance by characterizing depot-specific insulin responses and gain evidence that altered functionality of transcription factor forkhead box O-1 (FOXO-1) may play an important role in obesity-related endothelial dysfunction. Approach and Results-We intraoperatively collected paired subcutaneous and visceral adipose tissue samples from 56 severely obese (body mass index, 43±7 kg/m 2 ) and 14 nonobese subjects during planned surgical operations, and characterized depot-specific insulin-mediated responses using Western blot and quantitative immunofluorescence techniques. Insulin signaling via phosphorylation of FOXO-1 and consequent endothelial nitric oxide synthase stimulation was selectively impaired in the visceral compared with subcutaneous adipose tissue and endothelial cells of obese subjects. In contrast, tissue actions of insulin were preserved in nonobese individuals. Pharmacological antagonism with AS1842856 and biological silencing using small interfering RNA-mediated FOXO-1 knockdown reversed insulin resistance and restored endothelial nitric oxide synthase activation in the obese.
O besity and its associated cardiometabolic complications have developed into major healthcare problems worldwide. 1-3 Regional adiposity with central accumulation of ectopic visceral fat, in particular, has been closely associated with insulin resistance, endothelial dysfunction, and cardiovascular disease. [4] [5] [6] [7] [8] [9] [10] Although insulin resistance generally implies diminished actions of insulin in mediating glucose uptake, transport, and storage, insulin also exerts important physiological actions on the vasculature that regulate metabolism and blood flow via activation of endothelial nitric oxide synthase (eNOS) and endothelial nitric oxide (NO) production. 11, 12 Impaired insulin signaling in the vasculature has been shown to promote vascular inflammation, vasoconstriction, and progression of atherosclerotic plaques. [12] [13] [14] [15] [16] [17] [18] Although little is known about mechanisms of vascular insulin resistance, experimental models suggest that transcription factor forkhead box O-1 (FOXO-1) may be a potential key mediator involved in the pathogenic process. Experimental studies show that FOXO-1 downregulates eNOS protein expression, 19 and conversely endothelial ablation of FOXO-1 blunts atherosclerosis in animal models. 15 However, the role of FOXO-1 in the human vasculature and its regulation of eNOS bioaction in adipose tissue and obesity-related disease are completely unknown. In this study, we aimed to characterize the function of FOXO-1 in the pathophysiology of endothelial insulin resistance in human obesity, examine adipose depot-specific responses, and to differentiate findings in obese and nonobese individuals.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
were recruited. As displayed in Table 1 , obese individuals had higher body mass index, waist circumference, plasma insulin, homeostasis model assessment, hemoglobin A1C, high-sensitivity C-reactive protein, and cardiac risk factors.
Adipose Depot-Specific Insulin-Mediated eNOS Activation
As shown in Figure 1A , insulin stimulation significantly increased eNOS phosphorylation at activation site serine 1177 in the subcutaneous fat of obese subjects, which was blunted in the visceral depot. In contrast, phospho-eNOS (p-eNOS) increased significantly in both visceral and subcutaneous tissue in nonobese individuals ( Figure 1B ), and the same pattern was evident for phospho-AKT expression ( Figure I in the online-only Data Supplement). No interdepot difference in total basal eNOS protein expression was observed. Basal phosphorylation of eNOS was significantly higher in the visceral adipose depot from obese compared with nonobese individuals (P<0.05), but we found no difference in their subcutaneous depot (P=0.15). In addition, insulin stimulation did not promote differential activation of eNOS at alternative site serine 633 which has been shown to be a protein kinase-A site ( Figure II in the online-only Data Supplement). 20
Isolated Endothelial Cell Responses
Consistent with whole adipose tissue findings, endothelial cells isolated from fat tissues of obese subjects displayed impaired p-eNOS to insulin in the visceral compared with subcutaneous depot as displayed in Figure 2A . This corresponded with reduced NO production in endothelial cells from the visceral compared with subcutaneous depot ( Figure IIIA and IIIB in the online-only Data Supplement). Conversely, eNOS activation was preserved in both depots in nonobese subjects ( Figure 2B ). Representative quantitative immunofluorescence images of adipose endothelial cells from obese subjects are displayed in Figure 2C illustrating cellular insulin resistance in visceral fat. Total eNOS expression was similar in endothelial cells from both depots ( Figure IVA in the online-only Data Supplement).
Insulin Effects on FOXO-1
Impairment in phosphorylation and inactivation of FOXO-1 at serine 256 is implicated as a potential mechanism of insulin resistance in experimental models. In obese subjects, insulin induced FOXO-1 phosphorylation in subcutaneous fat which was blunted in the visceral depot ( Figure 3A ), whereas total FOXO-1 protein was similar in both regions ( Figure IVB in the online-only Data Supplement). In nonobese subjects, p-FOXO-1 to insulin was preserved in all depots ( Figure 3B ). Consistent with above data, we observed selective impairment in FOXO-1 signaling in endothelial cells isolated from visceral fat in only the obese ( Figure 4A and 4B).
Effect of Pharmacological and Biological FOXO-1 Inhibition
We examined whether FOXO-1 antagonism augments eNOS in visceral fat using specific inhibitor AS1842856. To confirm drug bioaction, we demonstrated diminished pyruvate dehydrogenase kinase-4 expression, a known downstream target of FOXO-1, 21 within 24 hours of pharmacological treatment (P<0.01; Figure 5A ). We observed upregulation of basal eNOS expression ( Figure VA in the online-only Data Supplement) and markedly improved (>3-fold) insulin-mediated p-eNOS in visceral fat in the presence of AS1842856 as displayed in Figure 5B . When we examined the specificity of this effect for endothelial cells, we observed significant improvement in insulin sensitivity ( Figure 5C ) that was also associated with increased basal eNOS protein ( Figure VB To exclude nonspecific off-target drug effects, we used complementary small interfering RNA methods to selectively diminish FOXO-1 activity in visceral fat which produced the desired decline in FOXO-1 compared with control as shown in Figure 6A . This was associated with significant increase in basal eNOS ( Figure VC in the online-only Data Supplement) and insulin-induced p-eNOS at Ser 1177 ( Figure 6B ), in similar magnitude to that observed with drug treatment. Based on our cumulative findings, a proposed schematic summary diagram of impaired insulin signaling in visceral obesity is displayed in Figure 7 . Finally, we observed a significant positive correlation between p-eNOS expression in visceral adipose endothelial cells and brachial arterial endothelium-dependent flow-mediated vasodilation prompting speculation for a pathophysiological adiposesystemic connection ( Figure VII in the online-only Data Supplement).
Discussion
We describe, for the first time, evidence of profound endothelial insulin resistance in the visceral adipose tissue of obese humans. We demonstrate diminished agonist-mediated activation of eNOS, representing a key early pathogenic step in the development of endothelial dysfunction and atherogenesis, which was associated with impaired FOXO-1 signaling. Both targeted pharmacological inhibition and biological small interfering RNA-mediated knockdown of FOXO-1 restored insulin sensitivity in human visceral adipose tissue. Our findings suggest that FOXO-1 modulation may represent a novel mechanism and potential therapeutic target to diminish vascular insulin resistance in obesity.
In addition to a wide range of metabolic actions, insulin modulates vascular function in part via stimulation of vascular NO production that controls vasodilation and arterial pressure. 14 Insulin regulates blood flow through activation of eNOS in vascular cells by binding to the IRS-1 receptor with subsequent Akt-mediated phosphorylation and activation of eNOS at Ser1177. Obese individuals with insulin resistance exhibit endothelial dysfunction, 22 and functional impairment in this pathway at the level of the endothelium is implicated in mechanisms of cardiovascular disease. 23 In animals, endothelium-specific deletion of the insulin receptor impairs eNOS bioavailability, promotes atherogenesis, and links to whole-body insulin resistance, hypertension, and ischemia. [24] [25] [26] [27] [28] Recent work from our laboratory demonstrated impaired insulin-stimulated eNOS phosphorylation, inflammation, and vasodilator dysfunction of endothelial cells isolated from the vascular wall of obese diabetics. 29 Compelling evidence is thus mounting that supports a mechanistic link between vascular insulin resistance and arterial disease and suggests that improving vascular insulin sensitivity may represent a therapeutic target. Clinical data consistently link degree of visceral adiposity burden to cardiometabolic risk, presumably owing to forced ectopic expansion and maladaptive remodeling of visceral fat, which leads to dysregulated release of proatherogenic adipocytokines that are implicated in the pathogenesis of systemic disease. 30 In contrast, clinical ramifications of subcutaneous expansion have been mixed with some reports even suggesting it as a favorable metabolic sink. 31, 32 Published data support the widely accepted notion that the visceral adipose tissue microenvironment, compared with subcutaneous fat, exhibits proinflammatory, pro-oxidant, and antiangiogenic properties associated with severe endothelial dysfunction. [33] [34] [35] Our novel finding of preserved insulin sensitivity in the visceral fat of nonobese subjects was remarkable and suggests that a pathogenic phenotype is not necessarily inherent to all visceral fat per se, but develops as a consequence of obesity. Although few clinical studies have been able to specifically examine tissue pathophysiology given the difficult nature of obtaining invasive intraabdominal biopsies from healthy lean subjects, at least 1 study reported normal microvasculature in the visceral fat of lean individuals which exhibited dysfunction only in obese conditions as in our findings. 36 Mechanisms underlying these associations remain relatively ill-defined from a molecular perspective. In this study, we focused on FOXO-1 because no prior study has examined its role in the pathogenesis of insulin resistance in vascular cells of obese humans. In experimental models, FOXO-1 has been shown to regulate eNOS by reducing its mRNA and protein expression via transcriptional repression. 15, 19, 37 Mimicking a hyperglycemic insulin-resistant state via exposure of cultured cells to high glucose activates FOXO-1 and blunts eNOS. 38 Animal models also suggest that endothelium-specific deletion of FOXO-1 delays progression of atherosclerosis and its knockdown improves eNOS bioavailability. 15 In our present study, we newly demonstrate that FOXO-1 expressed in human adipose tissue plays a significant role in mediating endothelial insulin resistance. To gain evidence for potential therapeutic modulation, we demonstrated that FOXO-1 inhibition using pharmacological antagonism improved eNOS protein expression and insulin-mediated phosphorylation at serine 1177, the commonly reported major index of eNOS activation, suggesting effects at both pre and post-translational levels, whereas no effect was seen on serine 633 phosphorylation. 20, 39 We affirmed our findings with complementary methodology using selective small interfering RNA-mediated of obese subjects, which has been described previously under disease conditions including obesity and likely represents a compensatory mechanism. 29 We acknowledge that regulation of FOXO-1 on p-eNOS responses is likely complex, and additional studies are required to further probe these regulatory pathways relevant to disease mechanisms in humans. Collectively, our findings suggest that dysfunctional FOXO-1 signaling plays a role in insulin resistant states, and its antagonism may have a beneficial effect on vascular biology, although no approved drug is yet currently available for clinical investigation. Although our findings may be largely specific to visceral adipose tissue, we observed an interestingly significant correlation between endothelial phenotype in visceral fat and systemic arterial endothelium-dependent vasodilation, which in turn has been shown to correlate with coronary responses and predict future cardiovascular events. 40 We have also previously shown agonist-induced p-eNOS in adipose endothelial cells to be a reliable functional and quantifiable cellular readout linked to vasomotor properties of human arterioles. 41 As such, pathophysiological mechanisms learned from the adipose microenvironment may provide valuable translational clues to systemic disease, as responses in the adipose vasculature have been shown to correlate with cardiac risk factors and systemic arterial function. 42 We emphasize the clinical relevance of elucidating molecular mechanisms of vascular insulin resistance in obesity particularly in relation to weight loss strategies to improve cardiovascular outcomes. Sustained weight loss with medical/dietary intervention is difficult and to date bariatric surgery stands alone as the sole durable weight reduction treatment shown to decrease long-term (>10year) cardiovascular mortality. 43 Although specific mechanisms of risk reduction are unknown, improved survival has been linked primarily to plasma insulin as the key biomarker of clinical response. 43 We have similarly recently shown that improved endothelial function with weight loss was directly tied to insulin sensitivity. 44 We thus affirm that preservation of insulin signaling may be a key homeostatic mechanism of blood vessels that develops perturbations in obesity, and elucidating disease mechanisms whose origins may lie within the visceral milieu may be highly clinically significant.
There are several limitations to our study. The experimental design was limited to a surgical population undergoing planned operations and bariatric subjects were severely obese (class III), thus findings may not be applicable to the general population or lesser degrees of obesity. However, this was counterbalanced by our ability to directly study properties of human visceral adipose tissue which would otherwise be impossible. Although we performed experiments on specimens immediately after surgical biopsy, technical applications may not exactly recapitulate the in vivo physiological environment. We examined interdepot responses but did not specifically compare body mass index categories. Most participants in the study were women, which reflects the general clinical practice nationally and sex differences in populations that seek weight loss treatments. 44, 45 We focused on serine 1177 phosphorylation site because the primary signal for eNOS stimulation however alternative activation sites may have additional roles. Lastly, the extent to which local insulin resistance in fat contributes to vascular dysfunction and cardiovascular disease systemically in obese states remains unclear.
In conclusion, we demonstrate the presence of endothelial insulin resistance in the visceral fat of obese subjects, which was reversible with FOXO-1 antagonism. FOXO-1 modulation may represent a novel therapeutic target to diminish vascular insulin resistance. With clinical data consistently linking visceral adiposity burden to cardiovascular risk, characterization of cellular derangements in the adipose microenvironment may provide clues to mechanisms of systemic disease.
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